Half-Year 2022 Financial and Clinical Trials Update

Lucentis Global sales CHFbn CER growth -17% Regional sales CER growth 1.0 0.8 0.6 0.4 0.2 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 572m • Impacted by switching to Vabysmo and upcoming biosimilar launches CER-Constant Exchange Rates US -17% Roche 182

View entire presentation